Dispatch Bio Showcases Dual-Platform Oncology Strategy and Preclinical SEND Advances

Dispatch Bio, a precision oncology company focused on solid tumors and engineered T cell therapies, spent the week spotlighting advances across its dual-platform strategy. The company emphasized its first-in-class Flare precision oncology platform and SEND, a T cell armoring technology designed to boost the performance of engineered T cell treatments.

Flare is described as a dual-stage approach that uses a tumor-specific virus to deliver a proprietary antigen into cancer cells, creating a beacon to guide therapeutics. Dispatch Bio positions this as a potentially universal framework for targeting solid tumors, though its ultimate impact will depend on future clinical validation, safety data, and regulatory outcomes.

In parallel, the company highlighted new preclinical data on SEND presented at the ASGCT 2026 meeting, where models showed strong anti-tumor activity and what Dispatch Bio characterized as a clean safety profile. SEND is intended to activate multiple signaling pathways simultaneously and could be deployed across autologous CAR T, in vivo CAR T, and TCR-based therapies.

Co-founder and Chief Platform Officer Lexus Johnson, Ph.D., discussed these platforms and recent preclinical findings in a BiotechTV interview with Brad Loncar, increasing the company’s visibility among industry stakeholders. The emphasis on overcoming key solid tumor challenges, including limited tumor-specific targets and immunosuppressive microenvironments, underscores Dispatch Bio’s bid to differentiate within competitive immuno-oncology and cell therapy markets.

While the programs remain preclinical, ongoing data generation and scientific engagement may position Dispatch Bio for future collaborations, licensing deals, or funding opportunities if forthcoming results remain supportive. The company also drew attention to external recognition of founders Carl June and Jeff Marrazzo as Disruptors of the Year, adding to its profile as it advances toward potential clinical milestones and strategic discussions.